Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts

被引：32

作者：

van der Helm, L. H. ^{[1
]}

Veeger, N. J. G. M. ^{[1
]}

van Marwijk Kooy, M. ^{[2
]}

Beeker, A. ^{[3
]}

de Weerdt, O. ^{[4
]}

de Groot, M. ^{[5
]}

Alhan, C. ^{[6
]}

Hoogendoorn, M. ^{[7
]}

Laterveer, L. ^{[8
]}

van de Loosdrecht, A. A. ^{[6
]}

Koedam, J. ^{[9
]}

Vellenga, E. ^{[1
]}

Huls, G. ^{[1
]}

机构：

[1] Univ Groningen, Univ Med Ctr Groningen, Dept Hematol, NL-9713 GZ Groningen, Netherlands

[2] Isala Klin, Dept Internal Med, Zwolle, Netherlands

[3] Spaarne Ziekenhuis, Dept Internal Med, Hoofddorp, Netherlands

[4] St Antonius Hosp, Dept Internal Med, Nieuwegein, Netherlands

[5] Med Spectrum Twente, Dept Internal Med, Enschede, Netherlands

[6] Vrije Univ Amsterdam Med Ctr, Dept Hematol, Amsterdam, Netherlands

[7] Med Ctr Leeuwarden, Dept Hematol, Leeuwarden, Netherlands

[8] Diaconessenhuis, Dept Internal Med, Meppel, Netherlands

[9] Celgene BV, Utrecht, Netherlands

来源：

LEUKEMIA RESEARCH | 2013年 / 37卷 / 08期

关键词：

Acute myeloid leukemia; Older age; Azacitidine; Bone marrow blast count; Predictors; ACUTE MYELOID-LEUKEMIA; INTERNATIONAL WORKING GROUP; CONVENTIONAL CARE REGIMENS; ELDERLY-PATIENTS; MYELODYSPLASTIC SYNDROMES; RESPONSE CRITERIA; OLDER PATIENTS; PHASE-III; AGE; CLASSIFICATION;

D O I：

10.1016/j.leukres.2013.03.022

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The efficacy of azacitidine has been demonstrated in acute myeloid leukemia (AML) patients with 20-30% bone marrow (BM) blasts, but limited data is available on patients with >= 30% blasts. We analyzed 55 newly diagnosed AML patients, treated with azacitidine. The overall response rate was 42%. Median overall survival (OS) was 12.3 months. We confirmed poor-risk cytogenetics, therapy-related AML, performance score >= 2, and white blood cell count >= 15x10(9)/L as independent adverse predictors for OS. The BM blast percentage, however, had no impact on OS (P=0.55). In conclusion, administration of azacitidine is effective in AML patients with 20-30% and >30% BM blasts. (C) 2013 Elsevier Ltd. All rights reserved.

引用

页码：877 / 882

页数：6

共 50 条

[21] First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab plus Azacitidine plus Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML)
Jaddaoui, Samiha
Bencharef, Hanaa
Addakiri, Sara
Dehbi, Hind
Lamchahab, Mouna
Quessar, Asmaa
Madani, Abdellah
Oukkache, Bouchra
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S255 - S256
[22] First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab plus Azacitidine plus Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML)
Zeidan, Amer M.
Westermann, Joerg
Kovacsovics, Tibor
Assouline, Sarit
Schuh, Andre C.
Kim, Hee-Je
Macias, Gabriela Rodriguez
Sanford, David
Luskin, Marlise R.
Stein, Eytan M.
Malek, Kamel
Lyu, Jiaying
Stegert, Mario
Esteve, Jordi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S255 - S255
[23] The comparative effectiveness of glasdegib in combination with low-dose cytarabine versus azacitidine by bone marrow blasts counts among patients with newly-diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.
van Beekhuizen, Sophie
Hu, Yannan
Gezin, Ana
Heeg, Bart
Bell, Timothy
Charaan, Majed
Brown, Andrew
Chan, Geoffrey
Cappelleri, Joseph C.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[24] Comparable Outcomes of Myeloablative Conditioning Regimen without ATG in CBT for Pediatric Patients with Hematological Malignancies with a Weight of More Than 30 Kilograms Vs. Less Than 30 Kilograms
Luo, Chenhui
Sun, Zimin
Xia, Lijun
BLOOD, 2018, 132
[25] Primary myelodysplastic syndromes (MDS) with less than 5% of blasts in bone marrow: study of 147 patients from two centers in Sao Paulo, Brazil
Velloso, E. R. P.
Pracchia, L. F.
Pinheiro, R. F.
Beitler, B.
Silva, M. R. R.
Chauffaille, M. L. L. F.
LEUKEMIA RESEARCH, 2007, 31 : S84 - S85
[26] Piaza: Non-interventional study on efficacy and safety of azacitidine (Vidaza®) in patients with myelodysplastic syndromes (MDS, Int-2 or high risk), AML (WHO 20-30% blasts), or CMML (10-29% bone marrow blasts without myeloproliferative disorder)
Wehmeyer, J.
Zaiss, M.
Losem, C.
Schmitz, S.
Neidig, C.
Teichmann, B.
Horde, J.
Trarbach, T.
Oncology Research and Treatment, 2015, 38 : 70 - 70
[27] Initial Results from SELECT-AML-1, a Phase 2 Study of Tamibarotene in Combination with Venetoclax and Azacitidine in RARA-Positive Newly Diagnosed AML Patients Ineligible for Standard Induction Chemotherapy
Kambhampati, Suman
McMahon, Christine M.
Eghtedar, Alireza
Pollyea, Daniel A.
de Botton, Stephane
Pigneux, Arnaud
Cherry, Mohamad
Ball, Brian J.
Borthakur, Gautam
Cluzeau, Thomas
Schiller, Gary J.
Hu, Beibei
Volkert, Angela
Gausman, Joanie Aasen
Hodgson, Graeme
Roth, David A.
Warlick, Erica D.
Kelly, Michael J.
Stein, Eytan
BLOOD, 2022, 140 : 3333 - 3335
[28] Outcome Of Patients With Myelodysplastic Syndrome (MDS) With Bone Marrow Blasts Between 10-30% Treated With Hypomethylating Agents Versus Intensive Chemotherapy
Nazha, Aziz
Kantarjian, Hagop M.
Jabbour, Elias
DiNardo, Courtney D.
Borthakur, Gautam
Daver, Naval G.
Faderl, Stefan H.
Ning, Jing
Qiao, Wei
Ravandi, Farhad
Kadia, Tapan M.
Pierce, Sherry R.
Cortes, Jorge E.
Garcia-Manero, Guillermo
BLOOD, 2013, 122 (21)
[29] Outcome of Patients with Myelodysplastic Syndrome (MDS) with Bone Marrow (BM) Blasts Between 10 to 30% Treated with Hypomethylating Agents Versus Intensive Chemotherapy
Nazha, Aziz
Kantarjian, Hagop M.
Cortes, Jorge E.
Faderi, Stefan
Pierce, Sherry A.
Daver, Naval G.
Pemmaraju, Naveen
Ravandi, Farhad
Borthakur, Gautam
Kadia, Tapan M.
Quintas-Cardama, Alfonso
Garcia-Manero, Guillermo
BLOOD, 2012, 120 (21)
[30] Flow Cytometric Enumeration of Peripheral Blood CD34+ Cells Predicts Bone Marrow Pathology in Patients with Less Than 1% Blasts by Manual Count
Jelic, Tomislav M.
Estalilla, Oscar C.
Vos, Jeffrey A.
Harvey, Gary
Stricker, Caitlin J.
Adelanwa, Ayodele O.
Khalid, Ahmed A.
Plata, Milton J.
JOURNAL OF BLOOD MEDICINE, 2023, 14 : 519 - 535

← 1 2 3 4 5 →